Skip to main content

Table 3 Summary of TEAEs and TRAEs in Patients Receiving ≥1 OnabotulinumtoxinA Treatment

From: Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Event, n (%) Safety Population N = 716
TEAE
  ≥ 1 TEAE 436 (60.9)
 Serious TEAE 75 (10.5)
 TEAE in those that discontinued treatment 32 (4.5)
TRAE
  ≥ 1 TRAE 131 (18.3)
 Serious TRAE 1 (0.1)
 TRAE in those that discontinued treatment 13 (1.8)
TRAE with incidence ≥1%
 Neck pain 29 (4.1)
 Eyelid ptosis 18 (2.5)
 Musculoskeletal stiffness 17 (2.4)
 Injection site pain 14 (2.0)
 Headache 12 (1.7)
 Muscular weakness 10 (1.4)
 Facial paresis 9 (1.3)
 Migraine 7 (1.0)
 Skin tightness 7 (1.0)
  1. TEAE treatment-emergent adverse event, TRAE treatment-related adverse event